Case Study Cloete van Vuuren ID Physician. 50 year old male Abscess over L parotid gland Cryptoccal meningitis 2010 PTB 2010 – completed 6/12 of Rx Stopped.

Slides:



Advertisements
Similar presentations
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Advertisements

TREATMENT OF TUBERCULOSIS, 2003
Global Health Case Studies – HIV and Tuberculosis Clinical Pearls in Diagnosis and Management Michael Tuggy, MD.
The Three Ds of Confusion Delirium, Depression, Dementia
Patient Initial Evaluation & Follow up. Pretreatment screening and evaluation: Initial evaluation serves to establish a baseline and may identify patients.
IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
TB recurrence & treatment B 陳名揚. Successful treatment more than one drug to which the organisms are susceptible appropriate doses take drugs regularly.
Case of MDR-TB from Haiti Christopher Kovacs MD Infectious Disease Fellow Cleveland Clinic.
IAS–USA Choosing the Initial Antiretroviral Regimen Paul A. Volberding, MD Professor of Medicine University of California San Francisco FINAL:
Clinical Case Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital Never smoked; does not ingest alcoholic beverages.
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
Unit 5: IPT Isoniazid TB Preventive Therapy
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
 Pulmonary Tuberculosis BY: MOHAMED HUSSEIN. Cause  Caused by Mycobacterium tuberculosis (M. tuberculosis)  Gram (+) rod (bacilli). Acid-fast  Pulmonary.
NYU Medical Grand Rounds Clinical Vignette Matthew B. Brown M.D. PGY-2 10/4/11 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Unit 9 Diagnosis and Treatment of Paediatric TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Unit 7 Treatment of TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Treatment Bed rest doesn’t affect outcome Hospitalisation: – Ill, smear positive, highly infectious patients – Esp in multi-drug resistant TB Continuous.
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Management of Tuberculosis: A Surgical Perspective Alfred Lardizabal, MD Associate Professor Division of Pulmonary and Critical Care Medicine UMDNJ-NJ.
Chapter 4 Cough or difficult breathing Case III. Case study: Mary is an 8 year old girl with cough and weight loss for some weeks.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
By: Michelle Russell.  To become familiar with the disease process of TB Transmission symptoms Precautions  Nursing Diagnoses  Interventions.
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
Clinical Case Female, 27 years of age Female, 27 years of age 3 rd year Internal Medicine resident at the Mexicali General Hospital 3 rd year Internal.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
SA TB Guidelines – The interface with Advanced Clinical Care Dr Kogie Naidoo Head: CAPRISA Treatment Research Programme Annual Workshop on Advanced Clinical.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
Anti-tuberculosis drugs. First-line drugs Isoniazid (INH or H) Rifampin (RMP or R) Ethambutol (EMB or E) Pyrazinamide (PZA or Z)
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
TB AND HIV/AIDS THE SITUATION AT BMC Care & Treatment Unit CME, 5/5/20166 PRESENTERS: Dr. Desideris Bernard, Dr. Magawa.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
TREATMENT OF TUBERCULOSIS: Prevention: BCG vaccination: It does not prevent infection but limits multiplication and spread of following infection so prevents.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
Treatment of TB Disease
Blasco P1, Breitenecker F1, Fontaine C1, Seangkla P2, Ruthaiwat J2.
Treatment of Latent TB Infection (LTBI)
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Dr Dawood Quiz questions.
Drug Resistant (DR) TB (Back to Basics)
بسم الله الرحمن الرحيم.
اهداف جهاني تعيين شده از سوي WHOبراي كشورها
Switch to DTG-containing regimen
Comparison of NNRTI vs NNRTI
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Tb: Screening & Diagnosis (1)
Switch to LPV/r monotherapy
Anti Tuberculosis Norah A A AL KHATHLAN MD 4/18/2019 Failure or MDR_TB.
Improving the Use of Medications to Treat Complex Health Problems in Resource-Poor Settings: Community-Based Examples from Haiti and Peru Jennifer Furin,
Comparison of NNRTI vs NNRTI
Switch to DTG-containing regimen
Treatment of Drug Resistant TB - Questions
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
Presentation transcript:

Case Study Cloete van Vuuren ID Physician

50 year old male Abscess over L parotid gland Cryptoccal meningitis 2010 PTB 2010 – completed 6/12 of Rx Stopped TDF/FTC/Efv 1 year ago

Pus aspirated – ZN pos, GeneXpert Rif Resistant

4

Sputum culture – Rif, INH resistant – Aminoglycoside and Moxifloxacin sensitive Initiated on Amikacin Moxifloxacin Teridizone Ethionamide PZA

ART 50 year old male Weight 33 kg CD4 = 49 sCreat = 70 Hemoglobin = 6.4 Calculated Creat clearance = 48.9 Unable to walk

Which ART Regime do you initiate this patient on? 1.Tenofovir/Emtricabine/Efavirenz 2.Zidovudine/lamivudine/Efavirenz 3.Stavudine/Lamivudine/Efavirenz 4.2NRTI + Nevirapine 5.2 NRTI + Aluvia

Delirium

Delirium? 1.Chronically ill and debilitated 2.Alcohol withdrawal 3.Secondary infection 4.Medication 5.Other

Which one of the following drugs is the most likely cause of his delirium? 1.Efavirenz 2.Moxifloxacin 3.Teridizone 4.Pyrazinamide 5.Ethionamide

Desperately trying to sort out his delirium: Biochemically normal No other infection identified Switched to Nevirapine Stop all TB drugs Haloperidol

Which side effects should be routinely monitored during the injection phase? 1.Renal function 2.Hearing test 3.Thyroid function 4.Liver function 5.Fullblood count

Delirium DVT

Is DVT’s associated with Tuberculosis or TB Rx? 1.Yes 2.No

Month 3 on MDR TB Rx: Due to his delirium it is impossible to do a hearing test Creatinine – 150 Hemoglobin increased to 10 g/dl Sputum culture negative

His Creatinine rises to 230 – will you stop the Amikacin? 1.Yes 2.No

Month 6 Can sit out – walk short distances Gaining weight 31kg – 45 kg More orientated Monthly sputum TB cultures negative Efavirenz – no effect on delirium

“BILATERAL SYMETRICAL HGH FREQ SNHL SEVERE TO PROFOUND (HEARING AID NEEDED) BUT HE DOESN’T WANT A HEARING AID.”

Discharge Will come to work daily – only “non-strenous”work Will DOT at ward

Does not come regularly for medication Often smells of alcohol Family? Social worker involved

Virological failure ? 1.Switch to AZT/3TC/Aluvia 2.Request Genotype 3.Tenofovir/3TC/Aluvia 4.Other

Adherence intervention DOT ART in the morning with MDRTB treatment

K103N, M184V

Disappeared for a month

Why is this patient not taking his treatment? 1.Treatment illiteracy 2.Social circumstances 3.Poor support 4.Mood disorders 5.Alcohol abuse

HIV Dementia

Conclusion Social circumstances Alcohol Delirium DVT HIV Dementia TB/MDR TB vs HIV “Human Nature”

Case 2

1.When did you initiate your first patient on ART? 1.< – None

Depressi on PNPN MI Choleste rol In-stent thrombosis

Aug10Sep 11Feb 12Oct 13 Total Cholestero l (mmol/l) Trig (mmol/l) 56 HbA1C11.5%

Aug 10 Sep 11Feb 12Oct 13Mar14Apr 15 Total Cholesterol (mmol/l ) Trig (mmol/l) HbA1C11.5%6.7%7.3%

Aug10Sep11Feb12Oct 13Mar14Apr 15Oct 15 Total Cholesterol (mmol/l) Trig (mmol/l) HbA1C11.5%6.7%7.3%

Case 3

In your experience, what is the most common reason for failing 2 nd line ART? 1.Not taking treatment 2.Not absorbing 3.Side effects 4.Mood disorders 5.Substance abuse

M41L D67N V75IM M184V L210W T215Y A98G V106I Y188L

Is she taking her treatment? 1.Yes 2.No

M41L D67N V75IM M184V L210W T215Y A98G V106I Y188L RHZE

What will you do? 1.Continue as is 2.Tdf/FTC/Raltegravir 3.Tdf/FTC/Raltegravir/Darunavir/r 4.Other

Conclusion Take nothing for granted (Double check everything and everybody)